YM-155 is an inhibitor of survivin, an inhibitor of apoptosis protein (IAP) that displays anticancer chemotherapeutic activity. YM-155 is currently undergoing clinical trials and shows efficacy in the treatment of prostate cancer. YM-155 induces apoptosis in cellular models of neuroblastoma and inhibits tumor growth in vivo. Additionally, this compound downregulates expression of Mcl-1 and increases activation of caspases 3 and 8, suppressing cell growth in leukemia cells.
| Cas No. | 781661-94-7 |
|---|---|
| Purity | ≥99% |
| Formula | C20H19N4O3Br |
| Formula Wt. | 443.29 |
| IUPAC Name | 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione;bromide |
| Synonym | YM155, Sepantronium bromide |
| Solubility | Water 89 mg/mL (200.77 mM) DMSO 55 mg/mL (124.07 mM) Ethanol 6 mg/mL (13.53 mM) |
| Appearance | Yellow solid |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Liang H, Zhang L, Xu R, et al. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2909-15. PMID: 24254560.
Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 2013 May 24;435(1):52-7. PMID: 23618862.
Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012 Apr;23(4):968-73. PMID: 21859898.
